Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt N/A
ARRY's Cash to Debt is ranked higher than
60% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. ARRY: N/A )
Ranked among companies with meaningful Cash to Debt only.
ARRY' s Cash to Debt Range Over the Past 10 Years
Min: 0.49  Med: 4.93 Max: No Debt
Current: N/A
Equity to Asset 0.13
ARRY's Equity to Asset is ranked lower than
90% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ARRY: 0.13 )
Ranked among companies with meaningful Equity to Asset only.
ARRY' s Equity to Asset Range Over the Past 10 Years
Min: -1.55  Med: 0.31 Max: 0.93
Current: 0.13
-1.55
0.93
F-Score: 6
Z-Score: -2.21
M-Score: -2.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -10.02
ARRY's Operating margin (%) is ranked higher than
65% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. ARRY: -10.02 )
Ranked among companies with meaningful Operating margin (%) only.
ARRY' s Operating margin (%) Range Over the Past 10 Years
Min: -410.11  Med: -105.86 Max: 3.18
Current: -10.02
-410.11
3.18
Net-margin (%) 0.60
ARRY's Net-margin (%) is ranked higher than
70% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. ARRY: 0.60 )
Ranked among companies with meaningful Net-margin (%) only.
ARRY' s Net-margin (%) Range Over the Past 10 Years
Min: -511.63  Med: -116.55 Max: 18.05
Current: 0.6
-511.63
18.05
ROE (%) 3.87
ARRY's ROE (%) is ranked higher than
79% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. ARRY: 3.87 )
Ranked among companies with meaningful ROE (%) only.
ARRY' s ROE (%) Range Over the Past 10 Years
Min: -132.15  Med: -55.01 Max: 110.67
Current: 3.87
-132.15
110.67
ROA (%) 0.28
ARRY's ROA (%) is ranked higher than
77% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. ARRY: 0.28 )
Ranked among companies with meaningful ROA (%) only.
ARRY' s ROA (%) Range Over the Past 10 Years
Min: -99.03  Med: -48.04 Max: 5.6
Current: 0.28
-99.03
5.6
ROC (Joel Greenblatt) (%) 197.38
ARRY's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. ARRY: 197.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARRY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -829.85  Med: -239.15 Max: 297.05
Current: 197.38
-829.85
297.05
Revenue Growth (3Y)(%) -32.60
ARRY's Revenue Growth (3Y)(%) is ranked lower than
78% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. ARRY: -32.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARRY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -36  Med: -6.00 Max: 39.4
Current: -32.6
-36
39.4
» ARRY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ARRY Guru Trades in Q1 2015

Jim Simons 1,054,652 sh (New)
Steven Cohen Sold Out
» More
Q2 2015

ARRY Guru Trades in Q2 2015

Jim Simons 811,995 sh (-23.01%)
» More
Q3 2015

ARRY Guru Trades in Q3 2015

Paul Tudor Jones 11,500 sh (New)
Ken Fisher 135,695 sh (New)
Jim Simons 929,428 sh (+14.46%)
» More
Q4 2015

ARRY Guru Trades in Q4 2015

Ken Fisher 135,695 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ARRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 41.60
ARRY's P/E(ttm) is ranked lower than
61% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 32.30 vs. ARRY: 41.60 )
Ranked among companies with meaningful P/E(ttm) only.
ARRY' s P/E(ttm) Range Over the Past 10 Years
Min: 41.57  Med: 74.36 Max: 777
Current: 41.6
41.57
777
PE(NRI) 58.20
ARRY's PE(NRI) is ranked lower than
71% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 32.00 vs. ARRY: 58.20 )
Ranked among companies with meaningful PE(NRI) only.
ARRY' s PE(NRI) Range Over the Past 10 Years
Min: 58.2  Med: 88.00 Max: 117.6
Current: 58.2
58.2
117.6
P/B 17.12
ARRY's P/B is ranked lower than
91% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. ARRY: 17.12 )
Ranked among companies with meaningful P/B only.
ARRY' s P/B Range Over the Past 10 Years
Min: 2.24  Med: 5.96 Max: 50.06
Current: 17.12
2.24
50.06
P/S 6.77
ARRY's P/S is ranked higher than
61% of the 620 Companies
in the Global Biotechnology industry.

( Industry Median: 10.07 vs. ARRY: 6.77 )
Ranked among companies with meaningful P/S only.
ARRY' s P/S Range Over the Past 10 Years
Min: 1.43  Med: 7.05 Max: 23.97
Current: 6.77
1.43
23.97
EV-to-EBIT 13.82
ARRY's EV-to-EBIT is ranked higher than
63% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 23.89 vs. ARRY: 13.82 )
Ranked among companies with meaningful EV-to-EBIT only.
ARRY' s EV-to-EBIT Range Over the Past 10 Years
Min: -44  Med: -6.00 Max: 320.9
Current: 13.82
-44
320.9
EV-to-EBITDA 12.29
ARRY's EV-to-EBITDA is ranked higher than
63% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.19 vs. ARRY: 12.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -76.5  Med: -7.10 Max: 165.9
Current: 12.29
-76.5
165.9
Current Ratio 3.65
ARRY's Current Ratio is ranked lower than
56% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. ARRY: 3.65 )
Ranked among companies with meaningful Current Ratio only.
ARRY' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.67 Max: 7.86
Current: 3.65
0.81
7.86
Quick Ratio 3.65
ARRY's Quick Ratio is ranked lower than
53% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ARRY: 3.65 )
Ranked among companies with meaningful Quick Ratio only.
ARRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.67 Max: 7.55
Current: 3.65
0.81
7.55
Days Sales Outstanding 69.87
ARRY's Days Sales Outstanding is ranked lower than
53% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. ARRY: 69.87 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.06  Med: 44.35 Max: 497.21
Current: 69.87
2.06
497.21
Days Payable 76.29
ARRY's Days Payable is ranked higher than
60% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. ARRY: 76.29 )
Ranked among companies with meaningful Days Payable only.
ARRY' s Days Payable Range Over the Past 10 Years
Min: 37.58  Med: 69.05 Max: 124.01
Current: 76.29
37.58
124.01

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 24.25
ARRY's Price/Net Current Asset Value is ranked lower than
86% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 4.85 vs. ARRY: 24.25 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ARRY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.24  Med: 5.69 Max: 48.85
Current: 24.25
2.24
48.85
Price/Tangible Book 17.12
ARRY's Price/Tangible Book is ranked lower than
88% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ARRY: 17.12 )
Ranked among companies with meaningful Price/Tangible Book only.
ARRY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.14  Med: 3.99 Max: 45.18
Current: 17.12
1.14
45.18
Price/Median PS Value 0.96
ARRY's Price/Median PS Value is ranked lower than
54% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. ARRY: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
ARRY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 0.93 Max: 3.07
Current: 0.96
0.21
3.07
Price/Graham Number 6.61
ARRY's Price/Graham Number is ranked lower than
87% of the 286 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. ARRY: 6.61 )
Ranked among companies with meaningful Price/Graham Number only.
ARRY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.24  Med: 0.79 Max: 10.36
Current: 6.61
0.24
10.36
Earnings Yield (Greenblatt) (%) 7.20
ARRY's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. ARRY: 7.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARRY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 2.50 Max: 7.3
Current: 7.2
0.3
7.3

More Statistics

Revenue(Mil) $71
EPS $ -0.04
Beta1.83
Short Percentage of Float18.79%
52-Week Range $2.78 - 8.59
Shares Outstanding(Mil)142.62

Analyst Estimate

Jun16
Revenue(Mil)
EPS($) -0.52
EPS without NRI($) -0.52

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AR2.Germany,
Array BioPharma Inc was incorporated in Delaware on February 6, 1998. It is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The Company's proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. In addition, pharmaceutical and biotechnology companies partner with the Company to discover and develop drug candidates across various therapeutic areas. The Company's proprietary clinical programs include three cancer drugs, binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (partnered with AstraZeneca. The Company's internal drug discovery programs include inhibitors that target Trk receptors for the treatment of oncology and other indications. The Company competes with companies that are engaged in the research and discovery, licensing, development and commercialization of drug candidates, including large pharmaceutical companies with internal discovery and development functions, biotech companies with competing products in the therapeutic areas it is targeting and contract research organizations that perform many of the functions it performs under its collaborations. The Company is subject to substantial regulation by governmental agencies in the U.S. and other countries.
» More Articles for ARRY

Headlines

Articles On GuruFocus.com
Screen: Stocks With Estimated Revenue Up 5% - January Jan 18 2016 
Insider Buys Round-up: Tenet Healthcare and Sprint Corp Aug 14 2015 
Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,310 Shares Mar 16 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,403 Shares Feb 11 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,272 Shares Jan 13 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,256 Shares Dec 10 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,220 Shares Nov 12 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,225 Shares Oct 13 2010 

More From Other Websites
ARRAY BIOPHARMA INC Files SEC form 10-Q, Quarterly Report Feb 05 2016
Edited Transcript of ARRY earnings conference call or presentation 2-Feb-16 2:00pm GMT Feb 02 2016
Array BioPharma To Present At The Leerink Partners Annual Global Healthcare Conference Feb 02 2016
Array Biopharma Inc Earnings Call scheduled for 9:00 am ET today Feb 02 2016
Array BioPharma reports 2Q loss Feb 02 2016
Array BioPharma reports 2Q loss Feb 02 2016
Q2 2016 Array Biopharma Inc Earnings Release - Before Market Open Feb 02 2016
ARRAY BIOPHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 02 2016
Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2016 Feb 02 2016
Dana-Farber Cancer Institute's Belfer Center announces Immuno-Oncology research collaboration with... Feb 01 2016
Dana-Farber Cancer Institute's Belfer Center announces Immuno-Oncology research collaboration with... Feb 01 2016
Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2016 On February 2,... Jan 26 2016
Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2016 On February 2,... Jan 26 2016
5 Stocks Insiders Love Right Now Jan 13 2016
Buffett, Starboard Among the Elite Investors to Disclose New Moves Jan 12 2016
QIAGEN Reaches Milestone With Portfolio of Master Collaboration Agreements for Pharma Companion... Jan 11 2016
Array BioPharma To Present At The Annual J.P. Morgan Healthcare Conference Jan 06 2016
Array BioPharma To Present At The Annual J.P. Morgan Healthcare Conference Jan 06 2016
Will Array BioPharma (ARRY) Crush Estimates at Its Next Earnings Report? Jan 06 2016
Why Array BioPharma (ARRY) Could Be Positioned for a Surge? Dec 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK